Advertisement

A Translational Approach to Novel Medication Development for Protracted Abstinence

  • Barbara J. MasonEmail author
  • Amanda E. Higley
Chapter
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 13)

Abstract

Alcohol dependence is a chronic relapsing disorder. Despite significant strides in the development of efficacious behavioral and pharmacological treatments for alcohol dependence, relapse rates remain very high. In this chapter, we review validated animal and human laboratory models for assessing risk of relapse in alcohol dependence and neurobiological treatment targets derived from such models. We suggest a translational approach to evaluate potential pharmacological treatments, using existing medications to validate and refine research paradigms across clinical and pre-clinical domains, with the aim of providing an accelerated framework for medications development in alcohol dependence. Lastly, empirical findings from proof-of-concept human laboratory studies are reviewed as we discuss the importance of selecting human laboratory models with predictive validity for the mechanism of action of the drug undergoing evaluation for efficacy in alcohol dependence.

Keywords

Human laboratory models Relapse Protracted abstinence Medication development Translational models Cue reactivity Craving 

Notes

Acknowledgments

Preparation of this review was supported by NIAAA grant numbers RO1AA12602 and R37AA014028 to BJM and the Pearson Center for Alcoholism and Addiction Research.

References

  1. Addolorato G, Leggio L, Abenavoli L, Gasbarrini G (2005) Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addict Behav 30:1209–1224PubMedGoogle Scholar
  2. Adinoff B, Junghanns K, Kiefer F, Krishnan-Sarin S (2005a) Suppression of the HPA axis stress-response: implications for relapse. Alcohol Clin Exp Res 29:1351–1355PubMedCentralPubMedGoogle Scholar
  3. Adinoff B, Krebaum SR, Chandler PA, Ye W, Brown MB, Williams MJ (2005b) Dissection of hypothalamic-pituitary-adrenal axis pathology in 1-month-abstinent alcohol-dependent men, part 1: adrenocortical and pituitary glucocorticoid responsiveness. Alcohol Clin Exp Res 29:517–527PubMedCentralPubMedGoogle Scholar
  4. Adinoff B, Risher-Flowers D, De Jong J, Ravitz B, Bone GH, Nutt DJ, Roehrich L, Martin PR, Linnoila M (1991) Disturbances of hypothalamic-pituitary-adrenal axis functioning during ethanol withdrawal in six men. Am J Psychiatry 148:1023–1025PubMedGoogle Scholar
  5. Adinoff B, Ruether K, Krebaum S, Iranmanesh A, Williams MJ (2003) Increased salivary cortisol concentrations during chronic alcohol intoxication in a naturalistic clinical sample of men. Alcohol Clin Exp Res 27:1420–1427PubMedGoogle Scholar
  6. Alling C, Balldin J, Bokstrom K, Gottfries CG, Karlsson I, Langstrom G (1982) Studies on duration of a late recovery period after chronic abuse of ethanol. A cross-sectional study of biochemical and psychiatric indicators. Acta Psychiatr Scand 66:384–397PubMedGoogle Scholar
  7. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, fourth edition, text revision. American Psychiatric Association, Washington, DCGoogle Scholar
  8. Annis HM, Sklar SM, Moser AE (1998) Gender in relation to relapse crisis situations, coping, and outcome among treated alcoholics. Addict Behav 23:127–131PubMedGoogle Scholar
  9. Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D (2004a) Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl) 173:32–40Google Scholar
  10. Anton RF, Moak DH, Latham PK, Waid LR, Malcolm RJ, Dias JK, Roberts JS (2001) Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 21:72–77PubMedGoogle Scholar
  11. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. AJ Psychiatry 156:1758–1764Google Scholar
  12. Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295:2003–2017PubMedGoogle Scholar
  13. Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S (2004b) A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 24:421–428PubMedGoogle Scholar
  14. Baker TB, Piper ME, McCarthy DE, Majeskie MR, Fiore MC (2004) Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychol Rev 111:33–51PubMedGoogle Scholar
  15. Baldwin HA, Hitchcott PK, File SE (1989) Evidence that the increased anxiety detected in the elevated plus-maze during chlordiazepoxide withdrawal is not due to enhanced noradrenergic activity. Pharmacol Biochem Behav 34:931–933PubMedGoogle Scholar
  16. Baldwin HA, Rassnick S, Rivier J, Koob GF, Britton KT (1991) CRF antagonist reverses the anxiogenic response to ethanol withdrawal in the rat. Psychopharmacology (Berl) 103:227–232Google Scholar
  17. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, Gustafsson L, Halldin J, Nilsson LH, Stolt G, Willander A (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27:1142–1149PubMedGoogle Scholar
  18. Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG (2008) Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 103:2035–2044PubMedGoogle Scholar
  19. Baltieri DA, De Andrade AG (2004) Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol 65:136–139PubMedGoogle Scholar
  20. Barrias J, Chabac S, Ferreira L, Fonte A, Potgieter AS, Teixeira de Sousa E (1997) Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatria Clinica 18:149–160Google Scholar
  21. Begleiter H, Porjesz B (1979) Persistence of a subacute withdrawal syndrome following chronic ethanol intake. Drug Alcohol Depend 4:353–357PubMedGoogle Scholar
  22. Berman JD, Cook DM, Buchman M, Keith LD (1990) Diminished adrenocorticotropin response to insulin-induced hypoglycemia in nondepressed, actively drinking male alcoholics. J Clin Endocrinol Metab 71:712–717PubMedGoogle Scholar
  23. Bernardy NC, King AC, Parsons OA, Lovallo WR (1996) Altered cortisol response in sober alcoholics: an examination of contributing factors. Alcohol 13:493–498PubMedGoogle Scholar
  24. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 22:573–579PubMedGoogle Scholar
  25. Betty Ford Institute (2007) What is recovery? A working definition from the Betty Ford Institute. J Subst Abuse Treat 33:221–228Google Scholar
  26. Bisaga A, Evans SM (2006) The acute effects of gabapentin in combination with alcohol in heavy drinkers. Drug Alcohol Depend 83(1):25–32PubMedGoogle Scholar
  27. Bokstrom K, Balldin J, Langstrom G (1989) Alcohol withdrawal and mood. Acta Psychiatr Scand 80:505–513PubMedGoogle Scholar
  28. Bokstrom K, Balldin J, Langstrom G (1991) Individual mood profiles in alcohol withdrawal. Alcohol Clin Exp Res 15:508–513PubMedGoogle Scholar
  29. Brady KT, Sonne SC (1999) The role of stress in alcohol use, alcoholism treatment, and relapse. Alcohol Res Health 23:263–271PubMedGoogle Scholar
  30. Breese GR, Chu K, Dayas CV, Funk D, Knapp DJ, Koob GF, Le DA, O’Dell LE, Overstreet DH, Roberts AJ, Sinha R, Valdez GR, Weiss F (2005) Stress enhancement of craving during sobriety: a risk for relapse. Alcohol Clin Exp Res 29:185–195PubMedCentralPubMedGoogle Scholar
  31. Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA (2008) A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 32:1429–1438PubMedCentralPubMedGoogle Scholar
  32. Brown RA, Lejuez CW, Kahler CW, Strong DR (2002) Distress tolerance and duration of past smoking cessation attempts. J Abnorm Psychol 111:180–185PubMedGoogle Scholar
  33. Carter BL, Tiffany ST (1999) Cue-reactivity and the future of addiction research. Addiction 94:349–351PubMedGoogle Scholar
  34. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B (2000a) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35:587–593PubMedGoogle Scholar
  35. Chick J, Howlett H, Morgan MY, Ritson B (2000b) United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35:176–187PubMedGoogle Scholar
  36. Cleck JN, Blendy JA (2008) Making a bad thing worse: adverse effects of stress on drug addiction. J Clin Invest 118:454–461PubMedCentralPubMedGoogle Scholar
  37. Cloninger CR (1987) Neurogenetic adaptive mechanisms in alcoholism. Science 236:410–416PubMedGoogle Scholar
  38. Cooney NL, Kadden RM, Litt MD, Getter H (1991) Matching alcoholics to coping skills or interactional therapies: two-year follow-up results. J Consult Clin Psychol 59:598–601PubMedGoogle Scholar
  39. Cooney NL, Litt MD, Morse PA, Bauer LO, Gaupp L (1997) Alcohol cue reactivity, negative-mood reactivity, and relapse in treated alcoholic men. J Abnorm Psychol 106:243–250PubMedGoogle Scholar
  40. Davidson D, Palfai T, Bird C, Swift R (1999) Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 23:195–203PubMedGoogle Scholar
  41. Davidson D, Saha C, Scifres S, Fyffe J, O’Connor S, Selzer C (2004) Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers. Addict Behav 29:1253–1258PubMedGoogle Scholar
  42. Davidson D, Swift R, Fitz E (1996) Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 20:732–739PubMedGoogle Scholar
  43. De Soto CB, O’Donnell WE, Allred LJ, Lopes CE (1985) Symptomatology in alcoholics at various stages of abstinence. Alcohol Clin Exp Res 9:505–512PubMedGoogle Scholar
  44. de Wit H, Soderpalm AH, Nikolayev L, Young E (2003) Effects of acute social stress on alcohol consumption in healthy subjects. Alcohol Clin Exp Res 27:1270–1277PubMedGoogle Scholar
  45. de Wit H, Svenson J, York A (1999) Non-specific effect of naltrexone on ethanol consumption in social drinkers. Psychopharmacology (Berl) 146:33–41Google Scholar
  46. De Witte P, Pinto E, Ansseau M, Verbanck P (2003) Alcohol and withdrawal: from animal research to clinical issues. Neurosci Biobehav Rev 27:189–197PubMedGoogle Scholar
  47. Drobes DJ, Anton RF, Thomas SE, Voronin K (2003) A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology 28:755–764PubMedGoogle Scholar
  48. Ehrenreich H, Schuck J, Stender N, Pilz J, Gefeller O, Schilling L, Poser W, Kaw S (1997) Endocrine and hemodynamic effects of stress versus systemic CRF in alcoholics during early and medium term abstinence. Alcohol Clin Exp Res 21:1285–1293PubMedGoogle Scholar
  49. Errico AL, Parsons OA, King AC, Lovallo WR (1993) Attenuated cortisol response to biobehavioral stressors in sober alcoholics. J Stud Alcohol 54:393–398PubMedGoogle Scholar
  50. Fox HC, Hong KA, Sinha R (2008) Difficulties in emotion regulation and impulse control in recently abstinent alcoholics compared with social drinkers. Addict Behav 33:388–394PubMedGoogle Scholar
  51. Furieri FA, Nakamura-Palacios EM (2007) Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68:1691–1700PubMedGoogle Scholar
  52. Galloway GP, Koch M, Cello R, Smith DE (2005) Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychiatry 5:18PubMedCentralPubMedGoogle Scholar
  53. Gastpar M, Bonnet U, Boning J, Mann K, Schmidt LG, Soyka M, Wetterling T, Kielstein V, Labriola D, Croop R (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 22:592–598PubMedGoogle Scholar
  54. Geerlings P, Ansoms C, van den Brink W (1997) Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 3:129–137Google Scholar
  55. George DT, Herion DW, Jones CL, Phillips MJ, Hersh J, Hill D, Heilig M, Ramchandani VA, Geyer C, Spero DE, Singley ED, O’Malley SS, Bishai R, Rawlings RR, Kunos G (2010) Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology (Berl) 208:37–44Google Scholar
  56. Gilman JM, Hommer DW (2008) Modulation of brain response to emotional images by alcohol cues in alcohol-dependent patients. Addict Biol 13:423–434PubMedGoogle Scholar
  57. Glautier S, Drummond DC (1994) Alcohol dependence and cue reactivity. J Stud Alcohol 55:224–229PubMedGoogle Scholar
  58. Gual A, Lehert P (2001) Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 36:413–418PubMedGoogle Scholar
  59. Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, Mengual I, Gonzalvo B, Segura L, Trujols J, Casas M (2002) A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 26:1381–1387PubMedGoogle Scholar
  60. Hammarberg A, Jayaram-Lindstrom N, Beck O, Franck J, Reid MS (2009) The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology (Berl) 205:53–62Google Scholar
  61. Heilig M, Egli M (2006) Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 111:855–876PubMedGoogle Scholar
  62. Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD (2001) Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 21:287–292PubMedGoogle Scholar
  63. Heinz A, Siessmeier T, Wrase J, Buchholz HG, Grunder G, Kumakura Y, Cumming P, Schreckenberger M, Smolka MN, Rosch F, Mann K, Bartenstein P (2005) Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry 162:1515–1520PubMedGoogle Scholar
  64. Heinz A, Siessmeier T, Wrase J, Hermann D, Klein S, Grusser S, Flor H, Braus D, Buchholz H, Grunder G, Schrechenberger M, Smolka M, Rosch F, Mann K, Bartenstein P (2004) Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry 161:1783–1789PubMedGoogle Scholar
  65. Hershon HI (1977) Alcohol withdrawal symptoms and drinking behavior. J Stud Alcohol 38:953–971PubMedGoogle Scholar
  66. Higgins RL, Marlatt GA (1975) Fear of interpersonal evaluation as a determinant of alcohol consumption in male social drinkers. J Abnorm Psychol 84:644–651PubMedGoogle Scholar
  67. Higley AE, Crane NA, Spadoni AD, Quello SB, Goodell V, Mason BJ (2011) Craving in response to stress induction in a human laboratory paradigm predicts treatment outcome in alcohol-dependent individuals. Psychopharmacology (Berl) 218:121–129Google Scholar
  68. Holter SM, Engelmann M, Kirschke C, Liebsch G, Landgraf R, Spanagel R (1998) Long-term ethanol self-administration with repeated ethanol deprivation episodes changes ethanol drinking pattern and increases anxiety-related behaviour during ethanol deprivation in rats. Behav Pharmacol 9:41–48PubMedGoogle Scholar
  69. Huang MC, Chen CH, Yu JM, Chen CC (2005) A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan. Addict Biol 10:289–292PubMedGoogle Scholar
  70. Hull JG, Young RD (1983) Self-consciousness, self-esteem, and success-failure as determinants of alcohol consumption in male social drinkers. J Pers Soc Psychol 44:1097–1109PubMedGoogle Scholar
  71. Janiri L, Martinotti G, Dario T, Reina D, Paparello F, Pozzi G, Addolorato G, Di Giannantonio M, De Risio S (2005) Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: a correlation study. Neuropsychobiology 52:37–44PubMedGoogle Scholar
  72. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ (2004) Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 61:905–912PubMedGoogle Scholar
  73. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677–1685PubMedGoogle Scholar
  74. Johnson BA, Roache JD, Ait-Daoud N, Zanca NA, Velazquez M (2002) Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (Berl) 160:408–413Google Scholar
  75. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 284:963–971PubMedGoogle Scholar
  76. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O’Malley SS, Swift RM (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641–1651PubMedGoogle Scholar
  77. Junghanns K, Backhaus J, Tietz U, Lange W, Bernzen J, Wetterling T, Rink L, Driessen M (2003) Impaired serum cortisol stress response is a predictor of early relapse. Alcohol Alcohol 38:189–193PubMedGoogle Scholar
  78. Junghanns K, Tietz U, Dibbelt L, Kuether M, Jurth R, Ehrenthal D, Blank S, Backhaus J (2005) Attenuated salivary cortisol secretion under cue exposure is associated with early relapse. Alcohol Alcohol 40:80–85PubMedGoogle Scholar
  79. Kaplan RF, Meyer RE, Stroebel CF (1983) Alcohol dependence and responsivity to an ethanol stimulus as predictors of alcohol consumption. Br J Addict 78:259–267PubMedGoogle Scholar
  80. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, Wiedemann K (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60:92–99PubMedGoogle Scholar
  81. Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C, Anton RF (2004) Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res 28:1710–1717PubMedGoogle Scholar
  82. Koob GF (1998) Circuits, drugs, and drug addiction. Adv Pharmacol 42:978–982PubMedGoogle Scholar
  83. Koob GF (2003) Alcoholism: allostasis and beyond. Alcohol Clin Exp Res 27:232–243PubMedGoogle Scholar
  84. Koob GF (2006) The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Addiction 101(1):23–30PubMedGoogle Scholar
  85. Koob GF (2008) A role for brain stress systems in addiction. Neuron 59:11–34PubMedCentralPubMedGoogle Scholar
  86. Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A, O’Dell LE, Parsons LH, Sanna PP (2004) Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 27:739–749PubMedGoogle Scholar
  87. Koob G, Kreek MJ (2007) Stress, dysregulation of drug reward pathways, and the transition to drug dependence. AJ Psychiatry 164:1149–1159Google Scholar
  88. Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278:52–58PubMedGoogle Scholar
  89. Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24:97–129PubMedGoogle Scholar
  90. Koob GF, Le Moal M (2008) Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci 363:3113–3123PubMedGoogle Scholar
  91. Koob GF, Lloyd GK, Mason BJ (2009) Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discovery 8:500Google Scholar
  92. Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217–238PubMedGoogle Scholar
  93. Kranzler HR, Armeli S, Tennen H, Blomqvist O, Oncken C, Petry N, Feinn R (2003) Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol 23:294–304PubMedGoogle Scholar
  94. Kranzler HR, Modesto-Lowe V, Nuwayser ES (1998) Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res 22:1074–1079PubMedGoogle Scholar
  95. Kranzler HR, Tennen H, Armeli S, Chan G, Covault J, Arias A, Oncken C (2009) Targeted naltrexone for problem drinkers. J Clin Psychopharmacol 29:350–357PubMedCentralPubMedGoogle Scholar
  96. Kranzler HR, Wesson DR, Billot L (2004) Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 28:1051–1059PubMedGoogle Scholar
  97. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345:1734–1739PubMedGoogle Scholar
  98. Ladewig D, Knecht T, Leher P, Fendl A (1993) Acamprosate—a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch 50:182–188PubMedGoogle Scholar
  99. Latt NC, Jurd S, Houseman J, Wutzke SE (2002) Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 176:530–534PubMedGoogle Scholar
  100. Le AD, Harding S, Juzytsch W, Watchus J, Shalev U, Shaham Y (2000) The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (Berl) 150:317–324Google Scholar
  101. Lhuintre JP, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G, Bosimare F, Hillemand B (1985) Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1:1014–1016PubMedGoogle Scholar
  102. Lindberg L, Brauer S, Wollmer P, Goldberg L, Jones AW, Olsson SG (2007) Breath alcohol concentration determined with a new analyzer using free exhalation predicts almost precisely the arterial blood alcohol concentration. Forensic Sci Int 168:200–207PubMedGoogle Scholar
  103. Litt MD, Cooney NL (1999) Inducing craving for alcohol in the laboratory. Alcohol Res Health 23:174–178PubMedGoogle Scholar
  104. Litt MD, Cooney NL, Kadden RM, Gaupp L (1990) Reactivity to alcohol cues and induced moods in alcoholics. Addict Behav 15:137–146PubMedGoogle Scholar
  105. Litt MD, Cooney NL, Morse P (2000) Reactivity to alcohol-related stimuli in the laboratory and in the field: predictors of craving in treated alcoholics. Addiction 95:889–900PubMedGoogle Scholar
  106. Littleton J (1995) Acamprosate in alcohol dependence: how does it work? Addiction 90:1179–1188PubMedGoogle Scholar
  107. Liu X, Weiss F (2002) Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci 22:7856–7861PubMedGoogle Scholar
  108. Lovallo WR, Dickensheets SL, Myers DA, Thomas TL, Nixon SJ (2000) Blunted stress cortisol response in abstinent alcoholic and polysubstance-abusing men. Alcohol Clin Exp Res 24:651–658PubMedGoogle Scholar
  109. Macey DJ, Schulteis G, Heinrichs SC, Koob GF (1996) Time-dependent quantifiable withdrawal from ethanol in the rat: effect of method of dependence induction. Alcohol 13:163–170PubMedGoogle Scholar
  110. Marlatt G (1985) Situational determinants of relapse and skill-training interventions. In: Marlatt G, Gordan JR (eds) Relapse prevention. Guilford Press, New York, pp 71–127Google Scholar
  111. Marlatt GA (1979) A cognitive-behavioral model of the relapse process. NIDA Res Monogr 25:191–200Google Scholar
  112. Marlatt GA (1990) Cue exposure and relapse prevention in the treatment of addictive behaviors. Addict Behav 15:395–399PubMedGoogle Scholar
  113. Marlatt GA, George WH (1984) Relapse prevention: introduction and overview of the model. Br J Addict 79:261–273PubMedGoogle Scholar
  114. Martinez D, Kim JH, Krystal J, Abi-Dargham A (2007) Imaging the neurochemistry of alcohol and substance abuse. Neuroimaging Clin N Am 17:539–555Google Scholar
  115. Martinotti G, Cloninger CR, Janiri L (2008a) Temperament and character inventory dimensions and anhedonia in detoxified substance-dependent subjects. Am J Drug Alcohol Abuse 34:177–183PubMedGoogle Scholar
  116. Martinotti G, Di Nicola M, Tedeschi D, Andreoli S, Reina D, Pomponi M, Mazza M, Romanelli R, Moroni N, De Filippis R, Di Giannantonio M, Pozzi G, Bria P, Janiri L (2010) Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol 24(9):1367–1374PubMedGoogle Scholar
  117. Martinotti G, Nicola MD, Reina D, Andreoli S, Foca F, Cunniff A, Tonioni F, Bria P, Janiri L (2008b) Alcohol protracted withdrawal syndrome: the role of anhedonia. Subst Use Misuse 43:271–284PubMedGoogle Scholar
  118. Mason BJ (2005) Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother 6:2103–2115PubMedGoogle Scholar
  119. Mason BJ, Goodman AM, Chabac S, Lehert P (2006) Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 40:383–393PubMedGoogle Scholar
  120. Mason BJ, Higley AE, Crane NA, Goodell V (2010) Evaluation of craving and sleep in a human laboratory study of acamprosate, naltrexone and placebo in alcohol dependent volunteers 15th Biennial International Society for Biomedical Research on alcoholism conference. France, ParisGoogle Scholar
  121. Mason BJ, Lehert P (2010) The effects of current subsyndromal psychiatric symptoms or past psychopathology on alcohol dependence treatment outcomes and acamprosate efficacy. Am J Addict 19:147–154PubMedGoogle Scholar
  122. Mason BJ, Light JM, Escher T, Drobes DJ (2008) Effect of positive and negative affective stimuli and beverage cues on measures of craving in non treatment-seeking alcoholics. Psychopharmacology (Berl) 200:141–150Google Scholar
  123. Mason BJ, Light JM, Williams LD, Drobes DJ (2009) Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol 14:73–83PubMedCentralPubMedGoogle Scholar
  124. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E (1994) A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 18:1162–1167PubMedGoogle Scholar
  125. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56:719–724PubMedGoogle Scholar
  126. McCaul ME, Wand GS, Eissenberg T, Rohde CA, Cheskin LJ (2000) Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology 22:480–492PubMedGoogle Scholar
  127. McGeary JE et al (2006) Genetic moderators of naltrexone’s effects on alcohol cue reactivity. Alcohol Clin Exp Res 30(8):1288–1296PubMedGoogle Scholar
  128. Miller PM, Hersen M, Eisler RM, Hilsman G (1974) Effects of social stress on operant drinking of alcoholics and social drinkers. Behav Res Ther 12:67–72PubMedGoogle Scholar
  129. Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, Swift R, Ray L, McGeary J (2008) Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 32:489–497PubMedGoogle Scholar
  130. Modesto-Lowe V, Burleson JA, Hersh D, Bauer LO, Kranzler HR (1997) Effects of naltrexone on cue-elicited craving for alcohol and cocaine. Drug Alcohol Depend 49:9–16PubMedGoogle Scholar
  131. Moller C, Wiklund L, Thorsell A, Hyytia P, Heilig M (1997) Decreased measures of experimental anxiety in rats bred for high alcohol preference. Alcohol Clin Exp Res 21:656–660PubMedGoogle Scholar
  132. Monti PM, Binkoff JA, Abrams DB, Zwick WR, Nirenberg TD, Liepman MR (1987) Reactivity of alcoholics and nonalcoholics to drinking cues. J Abnorm Psychol 96:122–126PubMedGoogle Scholar
  133. Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, Brown RA, Gulliver SB, Gordon A, Abrams DB (1999) Naltrexone’s effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 23:1386–1394PubMedGoogle Scholar
  134. Monti PM, Rohsenow DJ, Rubonis AV, Niaura RS, Sirota AD, Colby SM, Abrams DB (1993) Alcohol cue reactivity: effects of detoxification and extended exposure. J Stud Alcohol 54:235–245PubMedGoogle Scholar
  135. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, Weltman M, Bell JR, Richardson K, Haber PS (2006) Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 101:1451–1462PubMedGoogle Scholar
  136. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E (2001) Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 96:1565–1573PubMedGoogle Scholar
  137. Mossberg D, Liljeberg P, Borg S (1985) Clinical conditions in alcoholics during long-term abstinence: a descriptive, longitudinal treatment study. Alcohol 2:551–553PubMedGoogle Scholar
  138. Myrick H, Anton R, Voronin K, Wang W, Henderson S (2007) A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res 31:221–227PubMedGoogle Scholar
  139. Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K (2008) Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry 65:466–475PubMedCentralPubMedGoogle Scholar
  140. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E (2003) Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 38:135–141PubMedGoogle Scholar
  141. Nemeroff CB (1996) The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry 1:336–342PubMedGoogle Scholar
  142. Niaura R (2000) Cognitive social learning and related perspectives on drug craving. Addiction 95(Suppl 2): S155–S163PubMedGoogle Scholar
  143. Niederhofer H, Staffen W (2003) Acamprosate and its efficacy in treating alcohol dependent adolescents. Eur Child Adolesc Psychiatry 12:144–148PubMedGoogle Scholar
  144. O’Connor AB, Lang VJ (2007) Baclofen not comparable to diazepam for alcohol withdrawal. Am J Med 120: e5; author reply e7Google Scholar
  145. O’Farrell TJ, Allen JP, Litten RZ (1995) Disulfiram (antabuse) contracts in treatment of alcoholism. NIDA Res Monogr 150:65–91PubMedGoogle Scholar
  146. O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49:881–887PubMedGoogle Scholar
  147. O’Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl) 160:19–29Google Scholar
  148. Ooteman W, Koeter MW, Verheul R, Schippers GM, van den Brink W (2007) The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. Eur Neuropsychopharmacol 17:558–566PubMedGoogle Scholar
  149. Oslin D, Liberto JG, O’Brien J, Krois S, Norbeck J (1997) Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 5:324–332PubMedGoogle Scholar
  150. Oslin DW, Lynch KG, Pettinati HM, Kampman KM, Gariti P, Gelfand L, Ten Have T, Wortman S, Dundon W, Dackis C, Volpicelli JR, O’Brien CP (2008) A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res 32:1299–1308PubMedGoogle Scholar
  151. Overstreet DH, Knapp DJ, Breese GR (2002) Accentuated decrease in social interaction in rats subjected to repeated ethanol withdrawals. Alcohol Clin Exp Res 26:1259–1268PubMedCentralPubMedGoogle Scholar
  152. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P (1995) Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 30:239–247PubMedGoogle Scholar
  153. Palfai T, Davidson D, Swift R (1999) Influence of naltrexone on cue-elicited craving among hazardous drinkers: the moderational role of positive outcome expectancies. Exp Clin Psychopharmacol 7:266–273PubMedGoogle Scholar
  154. Pelc I, Le Bon O, Verbanck P, Lehert PH, Opsomer L (1992) Calcium-acetylhomotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo-controlled double-blind multi-centre study, in novel pharmacological interventions for alcoholism. In: Naranjo CASE (ed) Novel pharmacological interventions for alcoholism. Springer, New York, pp 348–352Google Scholar
  155. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P (1997) Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 171:73–77PubMedGoogle Scholar
  156. Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B (2005) Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 57:1128–1137PubMedGoogle Scholar
  157. Pitman RK, Orr SP, Forgue DF, de Jong JB, Claiborn JM (1987) Psychophysiologic assessment of posttraumatic stress disorder imagery in Vietnam combat veterans. Arch Gen Psychiatry 44:970–975PubMedGoogle Scholar
  158. Plawecki MH, Decarlo R, Ramchandani VA, O’Connor S (2007) Improved transformation of morphometric measurements for a priori parameter estimation in a physiologically-based pharmacokinetic model of ethanol. Biomed Signal Process Control 2:97–110PubMedCentralPubMedGoogle Scholar
  159. Plawecki MH, Han JJ, Doerschuk PC, Ramchandani VA, O’Connor SJ (2008) Physiologically based pharmacokinetic (PBPK) models for ethanol. IEEE Trans Biomed Eng 55:2691–2700PubMedCentralPubMedGoogle Scholar
  160. Poldrugo F (1997) Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 92:1537–1546PubMedGoogle Scholar
  161. Ramchandani VA, O’Connor S (2006) Studying alcohol elimination using the alcohol clamp method. Alcohol Res Health 29:286–290PubMedGoogle Scholar
  162. Rasmussen DD, Mitton DR, Green J, Puchalski S (2001) Chronic daily ethanol and withdrawal: 2. Behavioral changes during prolonged abstinence. Alcohol Clin Exp Res 25:999–1005PubMedGoogle Scholar
  163. Rassnick S, Heinrichs SC, Britton KT, Koob GF (1993) Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 605:25–32PubMedGoogle Scholar
  164. Ray LA, Hutchison KE (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 64:1069–1077PubMedGoogle Scholar
  165. Roberto M, Bajo M, Crawford E, Madamba SG, Siggins GR (2006) Chronic ethanol exposure and protracted abstinence alter NMDA receptors in central amygdala. Neuropsychopharmacology 31:988–996PubMedGoogle Scholar
  166. Roelofs SM (1985) Hyperventilation, anxiety, craving for alcohol: a subacute alcohol withdrawal syndrome. Alcohol 2:501–505PubMedGoogle Scholar
  167. Roelofs SM, Dikkenberg GM (1987) Hyperventilation and anxiety: alcohol withdrawal symptoms decreasing with prolonged abstinence. Alcohol 4:215–220PubMedGoogle Scholar
  168. Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, Colby SM, Kaplan GB (2000) Naltrexone’s effects on reactivity to alcohol cues among alcoholic men. J Abnorm Psychol 109:738–742PubMedGoogle Scholar
  169. Rohsenow DJ, Monti PM, Rubonis AV, Sirota AD, Niaura RS, Colby SM, Wunschel SM, Abrams DB (1994) Cue reactivity as a predictor of drinking among male alcoholics. J Consult Clin Psychol 62:620–626PubMedGoogle Scholar
  170. Roussaux JP, Hers D, Ferauge M (1996) Does acamprosate diminish the appetite for alcohol in weaned alcoholics? J Pharm Belg 51:65–68PubMedGoogle Scholar
  171. Rubonis AV, Colby SM, Monti PM, Rohsenow DJ, Gulliver SB, Sirota AD (1994) Alcohol cue reactivity and mood induction in male and female alcoholics. J Stud Alcohol 55:487–494PubMedGoogle Scholar
  172. Sanchis-Segura C, Spanagel R (2006) Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol 11:2–38PubMedGoogle Scholar
  173. Sass H, Soyka M, Mann K, Zieglgansberger W (1996) Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53:673–680PubMedGoogle Scholar
  174. Sayette MA, Monti PM, Rohsenow DJ, Gulliver SB, Colby SM, Sirota AD, Niaura R, Abrams DB (1994) The effects of cue exposure on reaction time in male alcoholics. J Stud Alcohol 55:629–633PubMedGoogle Scholar
  175. Schuckit MA, Irwin M, Brown SA (1990) The history of anxiety symptoms among 171 primary alcoholics. J Stud Alcohol 51:34–41PubMedGoogle Scholar
  176. Segal BM, Kushnarev VM, Urakov IG, Misionzhnik EU (1970) Alcoholism and disruption of the activity of deep cerebral structures. Clinical-laboratory research. Q J Stud Alcohol 31:587–601PubMedGoogle Scholar
  177. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB (1994) Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 18:879–885PubMedGoogle Scholar
  178. Singleton E, Tiffany S, Henningfield J (1994) Development and validation of a new questionnaire to assess craving for alcohol: problems of drug dependence. In: Proceeding of the 56th annual meeting, The College on Problems of Drug Dependence. National Institute on Drug Abuse, Rockville, MD, p 289Google Scholar
  179. Sinha R (2009) Modeling stress and drug craving in the laboratory: implications for addiction treatment development. Addict Biol 14:84–98PubMedCentralPubMedGoogle Scholar
  180. Sinha R, Fox HC, Hong KA, Bergquist K, Bhagwagar Z, Siedlarz KM (2009) Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals. Neuropsychopharmacology 34:1198–1208PubMedCentralPubMedGoogle Scholar
  181. Sinha R, Fuse T, Aubin LR, O’Malley SS (2000) Psychological stress, drug-related cues and cocaine craving. Psychopharmacology (Berl) 152:140–148Google Scholar
  182. Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, Gann H, Mann KF (2008) Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 28:317–324PubMedGoogle Scholar
  183. Staner L, Boeijinga P, Danel T, Gendre I, Muzet M, Landron F, Luthringer R (2006) Effects of acamprosate on sleep during alcohol withdrawal: a double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects. Alcohol Clin Exp Res 30:1492–1499PubMedGoogle Scholar
  184. Swift RM (1999) Medications and alcohol craving. Alcohol Res Health 23:207–213PubMedGoogle Scholar
  185. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000) Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35:202–209PubMedGoogle Scholar
  186. Tiffany ST (1999) Cognitive concepts of craving. Alcohol Res Health 23:215–224PubMedGoogle Scholar
  187. Uhart M, Wand GS (2009) Stress, alcohol and drug interaction: an update of human research. Addict Biol 14:43–64PubMedCentralPubMedGoogle Scholar
  188. Volkow N (2004) Imaging the addicted brain: from molecules to behavior. J Nucl Med 45:13N–24NPubMedGoogle Scholar
  189. Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876–880PubMedGoogle Scholar
  190. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O’Brien CP (1997) Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54:737–742PubMedGoogle Scholar
  191. Voltaire-Carlsson A, Hiltunen AJ, Koechling UM, Borg S (1996) Effects of long-term abstinence on psychological functioning: a prospective longitudinal analysis comparing alcohol-dependent patients and healthy volunteers. Alcohol 13:415–421PubMedGoogle Scholar
  192. Vuchinich S, Angelelli J, Gatherum A (1996) Context and development in family problem solving with preadolescent children. Child Dev 67:1276–1288PubMedGoogle Scholar
  193. Wand GS, Dobs AS (1991) Alterations in the hypothalamic-pituitary-adrenal axis in actively drinking alcoholics. J Clin Endocrinol Metab 72:1290–1295PubMedGoogle Scholar
  194. Watanabe KI, Ogihara-Hashizume A, Kobayashi Y, Mitsushio H, Komiyama T (2001) Impaired sleep during the post-alcohol withdrawal period in alcoholic patients. Addict Biol 6:163–169PubMedGoogle Scholar
  195. Weinstein A, Feldtkeller B, Feeney A, Lingford-Hughes A, Nutt D (2003) A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients. Addict Biol 8:229–232PubMedGoogle Scholar
  196. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347:1438–1442PubMedGoogle Scholar
  197. Zimmermann US, Mick I, Vitvitskyi V, Plawecki MH, Mann KF, O’Connor S (2008) Development and pilot validation of computer-assisted self-infusion of ethanol (CASE): a new method to study alcohol self-administration in humans. Alcohol Clin Exp Res 32:1321–1328PubMedGoogle Scholar
  198. Zorrilla EP, Valdez GR, Weiss F (2001) Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. Psychopharmacology (Berl) 158:374–381Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Committee on the Neurobiology of Addictive DisordersThe Scripps Research InstituteLa JollaUSA
  2. 2.The Pearson Center for Alcoholism and Addiction Research, Laboratory of Clinical PsychopharmacologyThe Scripps Research InstituteLa JollaUSA

Personalised recommendations